Top 50 Companies in Digital Neuro Biomarkers Market Worldwide 2025: Market Research Report (2024–2035)
RELEASE DATE: Aug 2025 Author: Spherical InsightsRequest Free Sample Speak to Analyst
Description
According to a research report published by Spherical Insights & Consulting, The Global Digital Neuro Biomarkers Market Size is projected to Grow from USD 707.4 Million in 2024 to USD 7883.5 Million by 2035, at a CAGR of 24.5% during the forecast period 2025–2035. The digital neuro biomarkers market is growing due to rising neurological disorders, aging populations, technological advancements in AI and wearables, demand for early diagnosis, remote monitoring, and government incentives.
Introduction
The digital neuro biomarkers market worldwide refers to the utilization of biometric data gathered through the use of wearables, mobile applications, and sensors in evaluating neurological function, monitoring such as mobility, speech, and cognitive reaction. These gadgets play a critical role in diagnosis, remote monitoring, and individualized management of conditions such as Alzheimer's, Parkinson's, and multiple sclerosis. Drivers of the growth are the increasing incidence of neurological disorders, the growing elderly population, advances in technology (AI or ML integration), and keen interest in previous non-invasive detection methods. Positive points are real-time, ongoing collection of data and integration with digital health platforms such as EHRs and telemedicine, seamlessly. There are possibilities in AI-driven analytics, mass-market mobile and wearable applications, and growing applications in drug discovery and clinical trials. Governments are supporting the industry, reimbursement programs, regulatory approvals, and programs such as India's National Digital Health Mission and the FDA's Digital Health Center of Excellence are enabling wider adoption.
Navigate Future Markets with Confidence: Insights from Spherical Insights LLP
The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.
Unlock exclusive market insights - Download the Brochure now and dive deeper into the future of the Digital Neuro Biomarkers Market.
Digital Neuro Biomarkers Market Size & Statistics
- The Market Size for Digital Neuro Biomarkers Was Estimated to be worth USD 707.4 Million in 2024.
- The Market Size is Going to Expand at a CAGR of 24.5% between 2025 and 2035.
- The Global Digital Neuro Biomarkers Market Size is anticipated to reach USD 7883.5 Million by 2035.
- North America is expected to generate the largest demand during the forecast period in the Digital Neuro Biomarkers Market
- Europe is expected to grow the fastest during the forecast period in the Global Digital Neuro Biomarkers Market.
Regional growth and demand
Europe is expected to grow the fastest during the forecast period in the digital neuro biomarkers market. Europe is experiencing the most rapid development in the digital neuro biomarkers market due to digital health, personalized medicine, and AI-based tool advancements. Monitoring in real-time helps in early detection and effective treatment of neurological disorders. Supportive regulations, healthcare spending, and technology healthcare partnerships also fuel market growth.
North America is expected to generate the largest demand during the forecast period in the digital neuro biomarkers market. North America dominates the digital neuro biomarkers market, attributable to the high prevalence of neurological disorders, a growing geriatric population, heavy healthcare expenditure, and supportive reimbursement strategies. The U.S. market dominates the region, spearheaded by significant investment in innovative technologies and revolutionary advancements in neuroscience by leading players in the industry.
Top 10 trends in the Digital Neuro Biomarkers Market
- Wearable devices and remote monitoring
- Mobile health applications
- Personalized medicine
- Advanced imaging technologies
- AI-driven drug development
- Pharma-tech collaborations
- Cloud-based data platforms
- Multi-modal biomarker approaches
- Focus on pediatric and geriatric populations
- Integration with electronic health records (EHRs)
1. Wearable devices and remote monitoring
Remote monitoring and wearable devices are transforming the digital neuro biomarkers market by allowing for uninterrupted, live monitoring of neurological health in the field. They offer insightful information on motor function, cognition, and vital signs to enable early diagnosis, tailored treatment, and effective management of neurological diseases with improved patient convenience.
2. Mobile health applications
Mobile health apps contribute significantly to the digital neuro biomarkers industry by providing available, convenient platforms for tracking cognitive and neurological function. They facilitate real-time data collection, tracking of symptoms, and remote patient interaction, improving early diagnosis, individualized care, and ongoing monitoring of neurological conditions.
3. Personalized medicine
Personalized medicine within the digital neuro biomarkers market utilizes unique biomarker information to customize treatments and interventions. This process improves diagnosis efficiency and therapy efficacy, allowing for personalized care plans for neurological illnesses, ultimately improving patient outcomes and minimizing unnecessary treatments by making more accurate, data-based decisions.
4. Advanced imaging technologies
Advanced imaging technologies boost the digital neuro biomarkers market by combining detailed brain scans with digital data, improving diagnosis and monitoring of neurological disorders. This convergence facilitates accurate detection of anomalies, facilitates early intervention, and facilitates monitoring disease progression for improved patient care.
5. AI-driven drug development
Drug development using AI speeds up the digital neuro biomarkers industry by leveraging biomarker data to discover drug targets, design optimal clinical trials, and forecast patient responses. It decreases development time, minimizes costs, and increases the success rate of new neurological drugs.
Empower your strategic planning:
Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the digital neuro biomarkers market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.
Top 20 Companies Leading the Digital Neuro Biomarkers Market
- Biogen Inc.
- Linus Health
- Roche Holding AG
- IBM Corporation
- Altoida Inc.
- Koneksa
- Merck KGaA
- AliveCor Inc.
- Huma
- Empatica Inc.
- Qura Therapeutics
- Apple Inc.
- Qiagen
- Eli Lilly Company
- Cognixion Inc.
- Aural Analytics
- Philips Healthcare
- ActiGraph LLC
- Thermo Fisher Scientific
- Neurotrack Technologies, Inc.
1. Biogen Inc.
Headquarters: Cambridge, Massachusetts, USA
Biogen leads the way in the adoption of digital health technologies in the field of neuroscience. In its Biogen Digital Health business, the company creates innovative solutions to track and measure neurological functions. Significantly, Biogen has partnered with Apple to initiate a virtual research study using Apple Watch and iPhone to track cognitive function and screen for the earliest warning signs of cognitive impairment, mild cognitive impairment. In addition, Biogen has collaborated with Indivi, licensing the Konectom platform, a digital biomarker system built on smartphones, to remotely monitor neurological functions so that it is possible to measure disease progression more accurately and regularly in diseases such as Parkinson's disease. These efforts are Biogen's focus on developing personalized and digital medicine in neuroscience.
2. Linus Health
Headquarters: Boston, Massachusetts, USA
Linus Health is a digital health company committed to revolutionizing brain health with sophisticated cognitive evaluation technologies. Their platform combines AI-powered tools to identify early cognitive decline, including Alzheimer's disease, by monitoring speech patterns, motor function, and visuospatial memory. Importantly, their Digital Clock and Recall (DCR) evaluation incorporates the DCT clock with word recall assessments for a complete assessment of cognitive capacity. The firm works with pioneering healthcare providers, research organizations, and pharmaceutical firms to advance early detection, optimize clinical trial efficiency, and facilitate individualized care plans for patients at risk for neurodegenerative diseases.
3. Roche Holding AG
Headquarters: Basel, Switzerland
Roche is at the leading edge of integrating digital biomarkers in neuroscience. Through its Roche Information Solutions business, the firm creates digital solutions that leverage smartphones and wearables to track neurological disorders such as Parkinson's and Alzheimer's disease. These technologies support ongoing, real-time monitoring of motor and cognitive abilities, with more precise and repeated measurements than the standard in-clinic assessments. Roche's digital biomarker technologies are applied to support clinical trials to improve accuracy, decrease the burden on patients, and improve the effectiveness of drug development workflows.
4. IBM Corporation
Headquarters: Armonk, New York, USA
IBM is a leader in combining AI and digital health platforms to develop the science of digital neuro biomarkers. With its Health Guardian platform, IBM facilitates ongoing, multimodal data capture through wearable devices, smartphones, and IoT sensors. Digital biomarkers can be developed using the platform to analyze various data types, including speech, motion, and physiological signals, to track neurological conditions such as Alzheimer's, Parkinson's, and schizophrenia. IBM's partnerships with the NIH and the Center for Brain Health also further improve its capabilities in early disease detection, personalized care, and clinical trial optimization.
5. Altoida Inc.
Headquarters: Washington, D.C., USA
Altoida Inc. is an innovative health technology company focused on digital biomarkers of neurological disorders. Their NeuroMarker Platform leverages augmented reality (AR) and artificial intelligence (AI) to perform rapid, self-administered cognitive tests within under 10 minutes. The platform records across motor, speech, and cognitive domains with objective measurements of brain function. In clinic and remote usage allows for early detection of Mild Cognitive Impairment (MCI) and Alzheimer's disease. Altoida's technology is based on more than 20 years of scientific research and has appeared in peer-reviewed journals such as Nature Digital Medicine.
Are you ready to discover more about the digital neuro biomarkers market?
The report provides an in-depth analysis of the leading companies operating in the global digital neuro biomarkers market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:
Company Profiles
- Biogen Inc.
- Business Overview
- Company Snapshot
- Products Overview
- Company Market Share Analysis
- Company Coverage Portfolio
- Financial Analysis
- Recent Developments
- Merger and Acquisitions
- SWOT Analysis
- Linus Health
- Roche Holding AG
- IBM Corporation
- Altoida Inc.
- Koneksa
- Merck KGaA
- AliveCor Inc.
- Huma
- Others.
Conclusion
The digital neuro biomarkers market utilizes wearable technology, mobile applications, and sensors to evaluate neurological operations such as cognition and movement to facilitate early disease diagnosis and individualized disease management for ailments such as Alzheimer's and Parkinson's. Drivers are increasing neurological conditions, aging populations, advances in AI, and non-invasive detection. Markets for opportunities include AI analytics, mobile, and drug discovery. Government policies, regulations, and reimbursement programs enhance adoption globally. Industry giants such as Biogen, Roche, IBM, and Altoida create innovative platforms for remote monitoring, cognitive testing, and optimizing clinical trials.
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?